Self-Injection devices allow patients with chronic diseases to gain control of their treatment schedule and their treatment setting, thus allowing greater independence and freedom in their social, domestic and professional lives. Self-injection may also offer psychological benefits over administration by healthcare professionals, including improved self-esteem. Removing the need to attend a clinic or hospital for regular injections also brings economic benefits to both the patient and the healthcare system. This economic benefit has been the major growth driving factor for this market. Increasing the prevalence of chronic autoimmune diseases like rheumatoid arthritis and cancer has also helped the growth as self-injections have applications in recovery from these illnesses.
However, stringent regulations for approval from regulatory authorities and lack of awareness of such devices in developing and underdeveloped economies have been restraining the growth of this market.
Scope of the Report
Self-Injection Devices are injections or wearable devices that can be used by the patient in-home setting to administer the medication himself. The market is segmented by product usage, application, and geography.
Key Market Trends
Pen Injectors are expected to cover a larger market share
Pen injectors are used for the subcutaneous delivery of biopharmaceuticals. Although they are also administered by professionals, these are primarily used for self-administration by the patient. First developed to replace vials and syringes for the treatment of diabetes with insulin, such injection devices have been an important part of the drug-delivery devices for a long time.
According to the 2018 World Health Organization report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This has attributed to the rise in the global prevalence of diabetes from 4.7% in 1980 to 8.5% in 2014. Moreover, diabetes prevalence has been rising more rapidly in the middle- and low-income countries. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Hence, the worldwide increase in diabetes and the growing pressure on health care costs that pushes toward patient self-injection means that their importance is expected to grow further in the future.
North America dominates the market
According to the Center for Disease Control and Prevention (CDC), in 2016, there were an estimated 15.5 million cancer survivors in the United States and this number is expected to increase to 20.3 million by 2026. According to an article by Ji Lin et al. published in Population Health Metrics Journal 2018, the projected number and percent of adults with diagnosed diabetes would increase from 22.3 million (9.1%) in 2014 to 39.7 million (13.9%) in 2030, and to 60.6 million (17.9%) in 2060. Also, the number of people with diabetes aged 65 years or older expected to increase from 9.2 million in 2014 to 21.0 million in 2030, and to 35.2 million in 2060. Hence, with the increasing prevalence of chronic diseases, the demand for self-injection devices, which are used for treatment or recovery from such diseases, is expected to increase.
The majority of the key player involved in research and manufacturing of self-injection devices are established in developed countries. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to rising awareness.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support